Live Breaking News & Updates on Humanistic Burden Associated

Janssen to Highlight Latest Research on Multiple Sclerosis at ACTRIMS Forum 2021
News provided by
Share this article
Share this article
TITUSVILLE, N.J., Feb. 24, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that its latest multiple sclerosis (MS) research will be presented at the 2021 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum from February 25-27. Nine Janssen-sponsored data abstracts on MS research will be presented, including real-world evidence highlighting the impact of fatigue in U.S. adults with relapsing MS (RMS); a study assessing the impact of MS fatigue on work productivity and activity impairment; and cross-sectional analyses of both the economic and humanistic burden associated with fatigue in relapsing-remitting MS. ....

United States , Jennifer Mcintyre , Chris Delorefice , Bill Martin , Us National Health , Americas Committee For Treatment , Sclerosis Association Of America , National Multiple Sclerosis Society , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Research In Multiple Sclerosis , None Of The Janssen Pharmaceutical Companies , Drug Administration , Actelion Pharmaceuticals Ltd , Exchange Commission , Companies Of Johnson , Idorsia Pharmaceuticals Ltd , European Medicines Agency , Multiple Sclerosis , Global Therapeutic Area Head , Janssen Research , Data Presentations Include , Fatigue Status , Disease Activity , Fatigue Symptom ,